TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amur Minerals ( (GB:CRTX) ) just unveiled an update.
CRISM Therapeutics has initiated the GMP manufacturing of ChemoSeed, a sustained-release implant containing irinotecan, for a Phase 2 clinical trial targeting glioblastoma. This marks a significant step towards addressing the unmet need for effective glioblastoma treatments and reinforces CRISM’s position in localized chemotherapy delivery. The trial aims to evaluate the safety and efficacy of ChemoSeed, potentially redefining post-surgical glioblastoma management by delivering high-dose chemotherapy directly to the tumor site while minimizing systemic toxicity.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based company specializing in innovative drug delivery technology aimed at improving the clinical performance of cancer treatments for solid tumors. Their lead product, ChemoSeed, is designed for localized delivery of chemotherapy drugs, particularly effective in treating glioblastoma by bypassing the blood-brain barrier.
Average Trading Volume: 55,109
Technical Sentiment Signal: Sell
Current Market Cap: £4.3M
Find detailed analytics on CRTX stock on TipRanks’ Stock Analysis page.